NCT00412334View on ClinicalTrials.gov

SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Copegus

1200-1600mg/day po

DRUG

Copegus

1000-1200mg/day po

DRUG

peginterferon alfa-2a [Pegasys]

360 micrograms sc weekly

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc twice weekly

Trial Locations (22)

13285

Marseille

13385

Marseille

31059

Toulouse

33604

Pessac

34295

Montpellier

36019

Châteauroux

38043

Grenoble

49033

Angers

54511

Vandœuvre-lès-Nancy

57038

Metz

59037

Lille

67091

Strasbourg

75651

Paris

75679

Paris

83407

Hyères

86021

Poitiers

87042

Limoges

93009

Bobigny

94000

Créteil

94010

Créteil

94804

Villejuif

06202

Nice

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00412334 - SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. | Biotech Hunter | Biotech Hunter